KDM5A and acute myeloid leukemia: Blocking the PHD domain of NUP98::PHF23 and NUP98::KDM5A fusion proteins by the FDA‐approved drug disulfiram has been shown to disrupt the H3K4me3 binding potential of fusion proteins, impair expression of HOXA/B, MEIS1 genes and increase cell death in AML mouse cells (Figure 4).83